Swissmedic

CIRS study on authorisation times for human medicinal products with new active substances confirms Swissmedic's competitiveness internationally

Original title: CIRS study on authorisation times for human medicinal products with new active substances confirms Swissmedic’s competitiveness internationally

Low obligation Framework Pharmaceuticals Switzerland Pharmaceuticals

06.07.2026

Read the official source ↗

Published by Swissmedic. HealthSignal links to the original document; the summary above is extracted from the source text.